May 25, 2026 PDF Available

Topic Overview

MedMentor EDU

ENT Study Notes

THE DEAF CHILD

Childhood Hearing Loss | Diagnosis | Management | Cochlear Implant

SECTION 1 | Introduction & Definitions

1.1 Definition of Deaf Child

A deaf child is a child under 18 years of age with a significant bilateral hearing loss that interferes with normal speech, language, and educational development.

Clinically significant: hearing loss >40 dB HL in the better ear
Includes prelingual (before speech) and postlingual (after speech development) onset

1.2 Definition of Hearing Impairment

Hearing impairment is any degree of reduction in the ability to perceive sound, ranging from mild to profound.

Measured by Pure Tone Audiometry (PTA)
Average of hearing thresholds at 500 Hz, 1000 Hz, 2000 Hz, 4000 Hz

1.3 WHO Classification of Hearing Loss

Grade	Hearing Threshold (dB HL)	Description
0 — Normal	25 dB or better	No impairment
1 — Slight	26–40 dB	Difficulty with faint speech
2 — Moderate	41–60 dB	Difficulty with normal speech
3 — Severe	61–80 dB	Difficulty with loud speech
4 — Profound	81 dB or more	Unable to understand even amplified speech

COMMON MCQ: WHO Grade 4 (Profound, >80 dB) is the cochlear implant candidate range — most commonly asked.

1.4 Epidemiology & Burden

1–3 per 1000 live births affected by significant hearing loss
Most common sensory disability in children globally
~50% of childhood deafness is preventable
Estimated 34 million children worldwide affected (WHO data)
India: ~6.3% of population has significant hearing loss; children are a major subset

1.5 Preventable Causes of Childhood Deafness

Immunization against rubella, measles, mumps
Antenatal care and TORCH screening
Neonatal hyperbilirubinemia management
Avoidance of ototoxic drugs in pregnancy and neonates
Prompt treatment of meningitis and otitis media
Noise exposure prevention

1.6 Importance of Early Diagnosis

Brain plasticity is maximal in first 3 years of life
Delayed diagnosis → missed critical period → irreversible language delay
1-3-6 Rule (JCIH):
- Screening by 1 month of age
- Diagnosis by 3 months
- Intervention by 6 months

HIGH-YIELD: 1-3-6 Rule (JCIH): Screen by 1 month, Diagnose by 3 months, Intervene by 6 months — extremely high-yield MCQ.

1.7 Critical Period of Speech & Language Development

Birth to 3 years: most critical period for auditory and speech development
Language centres in brain require early auditory input for maturation
Hearing loss during this period causes: absent speech development, poor language, educational failure
Late implantation (>5 years) results in poor cochlear implant outcomes

1.8 Effect of Deafness on Communication & Education

Absent or distorted speech development
Inability to follow verbal instructions in school
Social isolation and psychological impact
Learning disability and academic underperformance
Behavioral problems due to communication frustration

SECTION 2 | Normal Auditory & Speech Development

2.1 Auditory Development in Infancy

Hearing begins in utero by 20–24 weeks of gestation
Newborn responds to sudden loud sounds (Moro/startle reflex)
Auditory brainstem pathways mature by 2 years of age

2.2 Auditory Milestones

Age	Expected Auditory Response
0–3 months	Startle to loud sound; quietens to mother's voice
3–6 months	Turns eyes toward sound source
6–9 months	Localizes sound to side; responds to name
9–12 months	Localizes sound accurately above and below
12–18 months	Identifies familiar objects by name
18–24 months	Points to named body parts; follows simple commands

2.3 Speech Milestones

Age	Speech Expected
0–2 months	Cooing; vegetative sounds
2–6 months	Babbling begins; vowel sounds
6–9 months	Reduplicated babble (ma-ma, ba-ba)
9–12 months	Jargon; mama/dada with meaning
12–18 months	3–10 single words with meaning
18–24 months	2-word phrases; 50-word vocabulary
2–3 years	Short sentences; strangers understand ~75%
3–4 years	Full sentences; 90% intelligible to strangers

2.4 Red Flag Signs of Deafness

HIGH-YIELD: These are favorite viva/MCQ topics — memorize age-specific red flags.

Age	Red Flag Sign
0–3 months	No startle to loud sound; does not quieten to voice
3–6 months	No babbling; does not turn to sound
6–12 months	No localization of sound; no response to name
12–18 months	No single meaningful words
18–24 months	No 2-word phrases; vocabulary <10 words
>2 years	Speech regression; unclear articulation

2.5 Delayed Speech Indicators

Absence of babbling by 9 months
No single words by 12–14 months
No 2-word combinations by 24 months
Sudden loss of language (acquired hearing loss)
Speaks too loudly; watches lips closely (lip reading compensation)
Inattention in class; apparent behavioral problems

SECTION 3 | Classification of Deafness

3.1 By Time of Onset

Type	Definition	Key Point
Congenital	Present at or before birth	Usually genetic or intrauterine
Acquired	Develops after birth	Meningitis, ototoxicity, noise
Prelingual	Before speech development (<2 yrs)	Severe language delay
Postlingual	After speech development (>2 yrs)	Better prognosis for CI

COMMON MCQ: Prelingual deafness has WORSE cochlear implant prognosis compared to postlingual deafness.

3.2 By Type of Hearing Loss

Conductive Hearing Loss (CHL)

Defect in sound transmission through external or middle ear
Air-bone gap present on audiometry
Causes in children: otitis media with effusion, wax, aural atresia, ossicular abnormalities
Maximum loss: 60 dB HL
Usually treatable — surgical or medical

Sensorineural Hearing Loss (SNHL)

Defect in cochlea (sensory) or auditory nerve (neural)
No air-bone gap; both air and bone conduction reduced
Causes: genetic, meningitis, ototoxicity, congenital CMV
Usually permanent; managed with hearing aids or cochlear implant

Mixed Hearing Loss

Combined CHL and SNHL components
Air-bone gap present with elevated bone conduction threshold
Example: chronic otitis media with co-existing SNHL from ototoxic drops

Central Hearing Loss

Normal cochlea and auditory nerve but abnormal processing in CNS
Child hears but cannot interpret speech
Also called Auditory Processing Disorder (APD)

3.3 Syndromic vs Non-Syndromic Deafness

Feature	Syndromic	Non-Syndromic
Definition	Deafness + other organ involvement	Isolated hearing loss only
Proportion	~30% of genetic deafness	~70% of genetic deafness
Examples	Waardenburg, Usher, Pendred	DFNB1 (Connexin 26)
Inheritance	Various (AR, AD, X-linked)	Mostly AR

SECTION 4 | Etiology of Childhood Deafness

4.1 Genetic Causes

Overview

~50% of congenital deafness is genetic
Majority autosomal recessive (~80%)
Autosomal dominant: ~15–20%
X-linked and mitochondrial: ~1–2% each

Autosomal Recessive Deafness

Most common genetic cause
Parents are carriers but have normal hearing
DFNB1 locus — most common: Connexin 26 (GJB2 gene) mutation
- GJB2 mutation: most common cause of non-syndromic SNHL worldwide
- Disrupts gap junctions in cochlea → impaired K+ recycling → hair cell death

Autosomal Dominant Deafness

DFNA loci — multiple mutations
Often progressive hearing loss
Parent usually affected

X-Linked Deafness

Rare; affects males predominantly
Mutations in PRPS1, POU3F4 genes
POU3F4: associated with congenital X-linked perilymphatic gusher during stapes surgery

Mitochondrial Deafness

Maternally inherited mutations in mtDNA
1555A>G mutation: aminoglycoside hypersensitivity
- Even small doses of gentamicin cause profound SNHL in these patients

HIGH-YIELD: Connexin 26 / GJB2 mutation = most common cause of non-syndromic hereditary SNHL. 1555A>G mutation = aminoglycoside hypersensitivity.

4.2 Syndromic Deafness

Syndrome	Key Features	Type of HL	Inheritance
Waardenburg Syndrome	White forelock, heterochromia irides, dystopia canthorum, SNHL	SNHL	AD
Usher Syndrome	SNHL + Retinitis pigmentosa (progressive vision loss)	SNHL (profound)	AR
Pendred Syndrome	SNHL + Goitre (thyroid enlargement) + Mondini dysplasia	SNHL	AR
Alport Syndrome	SNHL + Nephritis + Ocular abnormalities	SNHL	X-linked
Jervell & Lange-Nielsen	Profound SNHL + Long QT syndrome (risk of sudden death)	SNHL	AR
Treacher Collins	Malar hypoplasia, micrognathia, EAC/middle ear atresia	CHL	AD
Down Syndrome	Trisomy 21; recurrent OM + occasional SNHL	CHL / Mixed	Chromosomal
CHARGE Syndrome	Coloboma, Heart defect, choanal Atresia, Retarded growth, GU and Ear anomalies	Mixed	AD

HIGH-YIELD: Jervell & Lange-Nielsen: SNHL + Long QT → sudden cardiac death — extremely important. Usher = SNHL + retinitis pigmentosa. Pendred = SNHL + goitre.

COMMON MCQ: Treacher Collins causes CONDUCTIVE hearing loss (middle ear atresia) — not SNHL.

4.3 Prenatal Causes — TORCH Infections

Agent	Type of HL	Key Points
Rubella	SNHL	Most common infectious cause; 1st trimester most dangerous; also causes heart defects, cataracts
CMV (Cytomegalovirus)	SNHL	Most common non-genetic congenital SNHL; may be asymptomatic at birth; progressive HL
Toxoplasmosis	SNHL	Intracranial calcifications; chorioretinitis
Syphilis	SNHL	Hutchinson teeth, interstitial keratitis; bilateral SNHL
Herpes simplex	SNHL	Rare; neonatal HSV meningitis

HIGH-YIELD: CMV = most common non-genetic cause of congenital SNHL. Rubella = most common infectious cause. Syphilis triad = deafness + interstitial keratitis + Hutchinson teeth.

Other Prenatal Causes

Maternal drug exposure: thalidomide, quinine, aminoglycosides
Radiation exposure in first trimester
Maternal diabetes → SNHL in child
Hypothyroidism in mother → congenital hearing loss (Pendred-like)

4.4 Perinatal Causes

Prematurity (<32 weeks gestation) → immature cochlea, NICU exposure
Low birth weight (<1500 g) — independent risk factor
Birth asphyxia — hypoxic-ischemic cochlear damage
Kernicterus — bilirubin deposits in cochlear nuclei and auditory brainstem
- Causes auditory neuropathy/dys-synchrony — BERA absent but OAE present
NICU stay >5 days — high-risk criterion for hearing screening
Ototoxic medications in neonates: furosemide, gentamicin, vancomycin
Mechanical ventilation — associated with aminoglycoside use and hypoxia

HIGH-YIELD: Kernicterus → Auditory Neuropathy Spectrum Disorder (ANSD): OAE present but ABR absent or abnormal. Very important MCQ.

4.5 Postnatal Causes

Bacterial meningitis: most common acquired cause of bilateral profound SNHL in children
- Streptococcus pneumoniae — most damaging organism
- Risk of cochlear ossification → urgent cochlear implant consideration
Viral infections: measles, mumps (unilateral SNHL), varicella
Chronic otitis media — predominantly conductive HL; SNHL if cholesteatoma or ototoxics
Noise-induced hearing loss — rock concerts, headphone use in adolescents
Head trauma — temporal bone fracture
Autoimmune inner ear disease — rare in children; bilateral progressive SNHL
Ototoxic drugs (see table below)

Drug Class	Examples	Type of HL
Aminoglycosides	Gentamicin, Streptomycin, Tobramycin, Amikacin	SNHL (permanent)
Loop diuretics	Furosemide, Ethacrynic acid	SNHL (usually reversible)
Antineoplastic	Cisplatin, Carboplatin	SNHL (permanent, dose-dependent)
Antimalarials	Quinine, Chloroquine	SNHL (reversible)
Salicylates	Aspirin	SNHL (reversible, tinnitus)
Vancomycin	Vancomycin (esp. with aminoglycosides)	SNHL

COMMON MCQ: Cisplatin causes dose-dependent, cumulative, irreversible SNHL beginning at high frequencies — very common exam question.

4.6 Congenital Inner Ear Anomalies

Anomaly	Description	Key Points
Michel Aplasia	Complete absence of inner ear	Severest form; cochlear implant contraindicated
Mondini Deformity	Cochlea has only 1.5 turns (normal 2.5)	Risk of CSF gusher during surgery; CI possible
Scheibe Dysplasia	Membranous labyrinth aplasia; bony labyrinth normal	Most common inner ear malformation; genetic
Common Cavity	Cochlea and vestibule fused into single cavity	No modiolus; CI possible with caution
Large Vestibular Aqueduct (EVA)	Vestibular aqueduct >1.5 mm at midpoint	Progressive SNHL; avoid head trauma
Cochlear Nerve Deficiency	Absent/hypoplastic cochlear nerve	Cochlear implant contraindicated

HIGH-YIELD: Scheibe dysplasia = most common inner ear malformation. Michel aplasia = most severe (CI contraindicated). Mondini = 1.5 cochlear turns + CSF gusher risk.

COMMON MCQ: EVA (Enlarged Vestibular Aqueduct) = progressive SNHL triggered by head injury or straining.

SECTION 5 | Clinical Evaluation

5.1 History Taking

Antenatal History

Maternal infections (TORCH screen), drug intake, radiation, diabetes, hypothyroidism
Family history of deafness (first and second-degree relatives)

Birth History

Prematurity, birth weight, APGAR scores
Birth asphyxia, prolonged jaundice, NICU admission
Ototoxic drug use in neonatal period

Developmental History

Age at onset of hearing concern
Speech milestones — age of babbling, first words, sentences
School performance, attention, behavioral issues

Family History

Consanguinity (autosomal recessive deafness risk)
Affected siblings or parents
Syndromic features in family

5.2 Examination

General Examination — Syndromic Features

Eyes: heterochromia (Waardenburg), retinal pigmentation (Usher)
Skin: white forelock (Waardenburg), hypopigmentation
Neck: goitre (Pendred), branchial sinuses (Branchio-oto-renal syndrome)
Face: Treacher Collins facies, CHARGE anomalies
Hands/feet: syndactyly, polydactyly
Renal: signs of nephropathy (Alport syndrome)

Otoscopic Examination

External canal: atresia, stenosis, wax, foreign body
Tympanic membrane: perforation, retraction, fluid (OME — amber TM, fluid level)
Middle ear: cholesteatoma, granulations

Neurological Examination

Cranial nerve assessment — facial nerve, balance
Developmental assessment: gross motor, fine motor, social
Vestibular assessment: balance, gait

SECTION 6 | Screening of Childhood Deafness

6.1 Universal Newborn Hearing Screening (UNHS)

Recommended for ALL newborns before hospital discharge
Gold standard screening tool: Otoacoustic Emissions (OAE) ± Automated ABR
Follows the 1-3-6 Rule (JCIH 2007 and 2019 guidelines)

6.2 JCIH High-Risk Factors for Hearing Loss

Joint Committee on Infant Hearing (JCIH) High-Risk Criteria:

Family history of permanent childhood SNHL
NICU stay >5 days OR any of the following: ECMO, assisted ventilation, ototoxic drugs, hyperbilirubinemia
In utero infections (TORCH)
Craniofacial anomalies including EAC and pinna anomalies
Physical findings associated with syndromes (Waardenburg, Usher, etc.)
Neurodegenerative disorders (Hunter syndrome, Charcot-Marie-Tooth)
Postnatal infections: bacterial meningitis, encephalitis
Head trauma
Parental concern regarding hearing/speech/language development

HIGH-YIELD: JCIH high-risk factors: NICU >5 days is THE most important perinatal risk factor for hearing screening.

6.3 Neonatal Screening Protocol

Stepwise Neonatal Hearing Screening Flowchart

All newborns: OAE screening before discharge

↓

Pass → Normal; follow-up if risk factors develop

↓

Fail → Repeat OAE in 2–4 weeks (avoid false positives from vernix/fluid)

↓

Fail again → Automated ABR (AABR)

↓

Fail AABR → Comprehensive audiological evaluation by 3 months

↓

Confirmed loss → Intervention (hearing aid/CI) by 6 months

6.4 OAE vs Automated ABR

Feature	OAE	Automated ABR (AABR)
Detects	Outer hair cell function	Brainstem auditory pathway
Time	~1–2 minutes	~15–20 minutes
Sensitivity	~80%	~99.7%
False positive	Higher (vernix, fluid, noise)	Lower
Auditory neuropathy	Normal OAE; ABR absent	Detects ANSD
Use	1st line screening	High-risk infants; 2nd line after failed OAE

HIGH-YIELD: Auditory Neuropathy Spectrum Disorder (ANSD): OAE PRESENT but ABR ABSENT/abnormal — hallmark finding. Caused by kernicterus, prematurity, cochlear nerve deficiency.

SECTION 7 | Hearing Assessment in Children

7.1 Behavioral Audiological Tests

Test	Age Group	Principle	Notes
Behavioral Observation Audiometry (BOA)	0–6 months	Observer notes reflexive behavioral response to calibrated sounds	Subjective; not reliable for threshold
Visual Reinforcement Audiometry (VRA)	6 months–2.5 years	Child conditioned to turn head; rewarded with visual stimulus	Gold standard 6 months–2 years
Conditioned Orientation Reflex (COR)	6 months–2 years	Similar to VRA; loudspeaker-based	Free-field; bilateral average
Play Audiometry	2–5 years	Child performs play task in response to sound	Standard test 2.5–5 years
Pure Tone Audiometry (PTA)	>5 years	Child responds (button/hand raise) to pure tone frequencies	Standard adult-type test
Speech Audiometry	>5 years (cooperative)	Speech reception threshold + word recognition score	Functional hearing assessment

COMMON MCQ: VRA is the gold standard behavioral test for 6 months to 2 years. Play audiometry for 2.5–5 years. PTA >5 years.

7.2 Objective Audiological Tests

Otoacoustic Emissions (OAE)

Generated by outer hair cells of cochlea
Types:
- TEOAE (Transient Evoked OAE): clicks → response from 1–4 kHz range; used in neonatal screening
- DPOAE (Distortion Product OAE): two simultaneous tones → used for ototoxicity monitoring and more frequency-specific data
OAE absent when hearing loss >25–30 dB HL
OAE normal in auditory neuropathy (ANSD)

BERA / ABR (Brainstem Evoked Response Audiometry)

Objective, no patient cooperation needed
Measures neural responses along auditory pathway to click/tone-burst stimuli
5 waves (I–V): Wave V is most reliable threshold estimator
Wave I: cochlear nerve; Wave III: superior olivary complex; Wave V: inferior colliculus
Normal wave V threshold: ~10–15 dB nHL
Used for: threshold estimation, retrocochlear lesions, neonatal screening, ANSD diagnosis, cochlear implant candidacy

HIGH-YIELD: ABR Wave V latency prolonged in retrocochlear lesions (acoustic neuroma). Absent Wave V in ANSD with present OAE = classic ANSD pattern.

ASSR — Auditory Steady State Response

Frequency-specific objective threshold measurement
More accurate than ABR for estimating hearing thresholds at specific frequencies
Used for hearing aid fitting prescription in infants
Excellent for severe-profound HL where ABR cannot estimate threshold

Tympanometry

Measures middle ear pressure and compliance

Type	Compliance	Pressure	Interpretation
Type A	Normal	Normal	Normal middle ear
Type As	Reduced	Normal	Otosclerosis, tympanosclerosis
Type Ad	Increased	Normal	Ossicular discontinuity, flaccid TM
Type B	Flat	Cannot determine	Otitis media with effusion (OME), perforation
Type C	Normal/reduced	Negative	Eustachian tube dysfunction

COMMON MCQ: Type B (flat) tympanogram = most common in children with OME (glue ear).

7.3 Radiological Evaluation

HRCT Temporal Bone: best for bony anatomy — canal atresia, middle ear, ossicles, Mondini, large vestibular aqueduct, cochlear ossification after meningitis
MRI Internal Auditory Canal: best for cochlear nerve, cochlear fluid, central auditory pathway, cochlear nerve deficiency
MRI Brainstem: auditory neuropathy, central causes

HIGH-YIELD: Pre-CI workup: HRCT temporal bone (bony anatomy) + MRI IAC (nerve presence). Both mandatory before cochlear implant surgery.

COMMON MCQ: Cochlear ossification after meningitis — detected on HRCT (white out of cochlea). Emergency indication for early cochlear implant before complete ossification.

SECTION 8 | Management

8.1 Medical Management

Treat reversible causes: antibiotics for meningitis, antimalarials for malaria-related HL
Manage otitis media with effusion: nasal decongestants, autoinflation, adenoidectomy + grommets
Steroids for sudden SNHL (>2 years): systemic or intratympanic
Prevent ototoxicity: monitor drug levels, use lowest effective dose, prefer alternatives
Vaccination: see Section 10

8.2 Rehabilitation

Early Intervention

Begin as soon as hearing loss confirmed; by 6 months of age
Parent-centered program: parent is primary facilitator
Home-based and clinic-based approaches

Auditory Verbal Therapy (AVT)

Uses residual hearing maximally with hearing aids/CI
Emphasizes listening and spoken language; no sign language
Aims for mainstream schooling
Best outcomes when started early (<2 years)

Lip Reading (Speech Reading)

Uses visual cues from speaker's lip and facial movements
Supplement to hearing aids; never a standalone substitute

Speech Therapy

Trained SLP works on articulation, voice, language skills
Essential component of CI rehabilitation

Family Counseling

Explain diagnosis, prognosis, and realistic expectations
Genetic counseling if hereditary etiology
Support groups

Educational Rehabilitation

Option	Description	Suitable For
Special School (Oral)	Spoken language focused; uses AVT	Mild-moderate HL; good hearing aid user
Special School (Sign Language)	Sign language as primary communication	Profound HL; poor CI candidates
Resource Room	Partial inclusion with resource teacher support	Moderate HL with hearing aids
Mainstream with FM System	Regular school with FM hearing loop	Post-CI, mild-moderate HL

8.3 Hearing Amplification

Hearing Aids

First-line for all types/degrees of hearing loss
Digital BTE (behind-the-ear) preferred for children
Custom earmolds required; change as child grows
Effective for mild-severe HL; limited benefit in profound HL
Hearing aid trial minimum 3–6 months before CI candidacy

Bone Conduction Devices

Indicated: CHL/mixed HL unsuitable for conventional hearing aids (atresia, chronic discharge)
BAHA (Bone-Anchored Hearing Aid):
- Implanted titanium screw in skull bone
- Bypasses external and middle ear; transmits sound through bone to cochlea
- Osseointegration needed (>5 years for implantation); use softband before 5 years

SECTION 9 | Cochlear Implant

9.1 Principles & Components

How It Works

Cochlear Implant Signal Processing Pathway

Microphone (external): picks up sound

↓

Speech processor (external): converts sound to digital code

↓

Transmitter coil (external): sends signal across skin

↓

Receiver-stimulator (internal, implanted): receives signal

↓

Electrode array (in cochlea): stimulates spiral ganglion neurons

↓

Auditory nerve → brain → sound perception

Components

External: microphone, speech processor, transmitter/headpiece
Internal (implanted): receiver-stimulator, electrode array
Electrode array: ~22 electrodes; placed in scala tympani of cochlea
Different electrodes stimulate different frequency regions (tonotopic)

9.2 Indications

Bilateral profound SNHL (>90 dB HL) — not benefiting from hearing aids after 3–6 months trial
Bilateral severe SNHL (70–90 dB HL) with poor hearing aid benefit in children
Single-sided deafness (SSD) — selected adult cases
Post-meningitis cochlear ossification — urgent/early CI before complete ossification
Age: optimal window 12 months to 3 years (prelingual); can be done from 6–12 months in selected cases

HIGH-YIELD: Optimal CI age: 12 months to 3 years. Earlier = better outcomes. Pre-lingual implantation before 2 years gives near-normal speech outcomes.

9.3 Contraindications

Cochlear nerve aplasia (absent cochlear nerve on MRI) — absolute contraindication
Michel aplasia (complete absence of inner ear)
Severe developmental delay with inability to benefit from auditory rehabilitation
Active middle ear infection — relative; treat first
Unrealistic parental expectations without commitment to rehabilitation

COMMON MCQ: Cochlear nerve aplasia on MRI = absolute contraindication to cochlear implant. Michel aplasia = bony contraindication.

9.4 Candidate Selection

Audiological Criteria

PTA average >70–90 dB HL bilaterally
Minimal speech perception scores with optimally fit hearing aids (<30–50% on open-set sentence tests in adults)
Failed hearing aid benefit after adequate trial

Radiological Criteria

HRCT: patent cochlea, no complete ossification, patent cochlear turns
MRI IAC: cochlear nerve present (mandatory)

Psychological & Rehabilitation Assessment

Parental motivation and commitment to rehabilitation program
Realistic expectations
Absence of severe learning disability

9.5 Surgical Aspects

Approach

Postauricular incision → cortical mastoidectomy → posterior tympanotomy (facial recess approach)
Cochleostomy or extended round window approach to enter scala tympani
Electrode array inserted via soft surgery technique to preserve residual hearing

Soft Surgery Technique

Preserves cochlear microstructure
Allows hearing preservation for electric-acoustic stimulation (EAS) in residual low-frequency hearing
Slow, atraumatic electrode insertion

Neural Response Telemetry (NRT)

Intraoperative testing of electrode-nerve interface
Confirms cochlear nerve responses
Guides programming/mapping

9.6 Postoperative Rehabilitation

Device activation (switch-on): 4–6 weeks post-surgery
Mapping/Programming: programming of each electrode's threshold (T-level) and comfortable level (C-level)
Repeated mapping sessions over months to optimize performance
Auditory rehabilitation: structured listening program
Speech therapy: intensive speech and language work
Progress monitoring: speech perception tests, language assessments

CLINICAL PEARL: CI outcomes are maximized when: early implantation (<2 years), strong parental involvement, intensive AVT, and mainstream educational integration are combined.

9.7 Bilateral Cochlear Implantation

Feature	Sequential	Simultaneous
Timing	Two separate surgeries, interval >6 months	Both ears in single surgery
Advantage	2nd ear if 1st fails; hearing assessment after 1st	Single anesthetic; shorter interval to binaural hearing; lower total cost
Disadvantage	Longer period of unilateral hearing; 2 anesthetics	Higher surgical risk; 2nd ear cannot benefit from 1st CI experience
Preferred in	Financial/system constraints; older children	Young infants; when simultaneous benefit outweighs risks

CLINICAL PEARL: Bilateral CI provides binaural hearing advantages: sound localization, improved speech in noise, auditory streaming.

9.8 Complications of Cochlear Implant

Complication	Details
Device failure (hard failure)	Internal device malfunction; requires re-implantation
Facial nerve injury	Rare (<1%); most at second genu or mastoid segment
CSF leak / Perilymph gusher	Risk with Mondini deformity; manage with packing
Wound infection	Superficial; rare serious deep infection
Meningitis	Post-CI meningitis risk (pneumococcal); vaccination essential
Flap necrosis	Skin flap breakdown over implant
Electrode migration/extrusion	Device displacement
Cochlear ossification	Post-meningitis; may prevent full insertion
Tinnitus/vertigo	Usually temporary

HIGH-YIELD: Post-CI meningitis risk: caused by Streptococcus pneumoniae traveling via electrode. Mandatory vaccinations before CI: Pneumococcal + Meningococcal + Hib.

9.9 Vaccination Protocol for CI Candidates

Pneumococcal vaccine (PCV13 + PPSV23) — most critical
Haemophilus influenzae type b (Hib) vaccine
Meningococcal vaccine
All vaccines should be given at least 2 weeks before surgery if possible

SECTION 10 | Prognosis & Prevention

10.1 Consequences of Delayed Diagnosis

Permanent language deprivation — cannot be fully reversed after critical period
Auditory deprivation: central auditory pathway fails to mature
Learning disability: academic failure
Psychological sequelae: social isolation, low self-esteem, depression
Poor CI outcomes if implantation delayed beyond 5–7 years

10.2 Prevention

Primary Prevention

Universal immunization: MMR (measles, mumps, rubella), Hib, pneumococcal, meningococcal
Antenatal TORCH screening and treatment
Avoidance of ototoxic drugs during pregnancy
Genetic counseling for high-risk couples (consanguinity, affected sibling)
Safe noise exposure: education, hearing protection

Secondary Prevention

Universal newborn hearing screening — 1-3-6 Rule
Early hearing aid fitting
Early speech therapy and educational placement

Tertiary Prevention

Cochlear implantation for profound SNHL
Auditory verbal therapy to maximize use of implant
Mainstream educational integration

SECTION 11 | Master Comparison Tables

11.1 Conductive vs Sensorineural vs Mixed HL

Feature	CHL	SNHL	Mixed
Site of lesion	External/middle ear	Cochlea/auditory nerve	Both
Air conduction	Reduced	Reduced	Reduced
Bone conduction	Normal	Reduced	Reduced (less than AC)
Air-bone gap	Present (>10 dB)	Absent	Present
Rinne test	Negative (BC>AC)	Positive (AC>BC, both reduced)	May be negative
Weber lateralization	Lateralizes to worse ear	Lateralizes to better ear	Variable
Max severity	60 dB HL	120 dB HL (profound)	120 dB HL
Management	Often surgical/medical	Hearing aid / CI	Combined

11.2 OAE vs BERA (ABR)

Feature	OAE	BERA/ABR
Origin	Outer hair cells	Auditory pathway (CN VIII → inferior colliculus)
Reflects	Cochlear function	Neural synchrony along auditory pathway
Cooperation	Not needed	Not needed (sedation in children)
Frequency specific	Partial (DPOAE better)	Poor (click ABR); good (tone burst ABR)
Threshold estimate	Indirect (present/absent)	Direct threshold estimation
ANSD pattern	Present (normal)	Absent / severely abnormal
Use	Screening	Diagnosis + threshold + retrocochlear

11.3 Hearing Aid vs Cochlear Implant

Feature	Hearing Aid	Cochlear Implant
Mechanism	Amplifies residual hearing	Bypasses cochlea; directly stimulates auditory nerve
Surgery	Not required	Required
Degree of HL	Mild–severe (best); some profound	Severe–profound SNHL
Cochlea required	Must have residual hair cells	Spiral ganglion neurons sufficient
Reversible	Yes	No (device is permanent)
Best age to start	As early as possible	<2 years for best outcomes
Outcome	Good for mild-moderate HL	Near-normal speech for early bilateral CI

11.4 Prelingual vs Postlingual Deafness

Feature	Prelingual	Postlingual
Onset	Before speech development (<2 years)	After speech development (>2 years)
Language impact	Severe; no spontaneous speech	Speech retained initially; deteriorates without input
CI timing	Best <2 years	Good at any age; faster re-adaptation
Prognosis	Depends on age of CI	Generally better
Example	Congenital SNHL	Meningitis at age 5; sudden SNHL

11.5 Key Genetic Syndromes — Quick Comparison

Syndrome	HL Type	Other Feature	Inheritance
Waardenburg	SNHL	White forelock, heterochromia	AD
Usher	SNHL (profound)	Retinitis pigmentosa	AR
Pendred	SNHL	Goitre + Mondini	AR
Alport	SNHL	Nephritis	X-linked
Jervell-Lange-Nielsen	SNHL (profound)	Long QT — sudden death	AR
Treacher Collins	CHL	Malar hypoplasia, micrognathia	AD
Branchio-oto-renal	Mixed	Branchial cysts, renal anomalies	AD

SECTION 12 | High-Yield Exam Pearls

12.1 Epidemiology & General

1-3-6 Rule: Screen by 1 month → Diagnose by 3 months → Intervene by 6 months
Most common non-genetic congenital SNHL = CMV
Most common genetic cause of non-syndromic SNHL = Connexin 26 (GJB2) mutation
Most common cause of acquired SNHL in children = Bacterial meningitis
Most severe inner ear malformation = Michel aplasia (CI contraindicated)
Most common inner ear malformation = Scheibe dysplasia

12.2 Audiology

VRA = gold standard behavioral test for 6 months–2 years
ANSD: OAE present, ABR absent — caused by kernicterus, prematurity
Type B flat tympanogram = OME (glue ear) in children
ASSR: best objective frequency-specific test for infants; aids in hearing aid fitting
Wave V of ABR = most reliable wave for threshold estimation
Cisplatin: irreversible, dose-dependent SNHL at high frequencies first

12.3 Cochlear Implant

Optimal CI age: <2 years for best speech outcomes
CI contraindications: absent cochlear nerve (MRI), Michel aplasia
Pre-CI mandatory vaccines: Pneumococcal + Hib + Meningococcal (at least 2 weeks before)
Post-meningitis: urgent CI before cochlear ossification occurs
Mondini deformity → CI possible but risk of CSF gusher during surgery
EVA (Enlarged Vestibular Aqueduct) → progressive SNHL; avoid head trauma

12.4 Syndromes

Jervell-Lange-Nielsen = SNHL + Long QT → cardiac arrest; dangerous → ECG mandatory
Usher syndrome = SNHL + progressive blindness (retinitis pigmentosa)
Pendred = SNHL + goitre + Mondini dysplasia + perchlorate discharge test positive
Alport = SNHL + hematuria + nephritis + ocular anomalies; X-linked
Waardenburg Type I: dystopia canthorum (wider spacing of medial canthi) — distinguishes from Type II

12.5 Embryology / Congenital

1555A>G mitochondrial mutation: aminoglycoside hypersensitivity → profound SNHL even with single dose
Rubella: 1st trimester = most dangerous; causes SNHL + congenital heart disease + cataracts
Congenital X-linked deafness with POU3F4 mutation → perilymphatic gusher during stapes surgery
Cochlear nerve deficiency → CI contraindicated; consider auditory brainstem implant (ABI)

SECTION 13 | Important Diagrams & Figures

13.1 Anatomy Diagrams

Image 1

Normal ear anatomy — external, middle, inner ear labeled cross-section
Cochlear cross-section showing scala vestibuli, scala media, scala tympani, Organ of Corti, basilar membrane
Organ of Corti: inner hair cells, outer hair cells, tectorial membrane, pillar cells